Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: Low doses of the drug FTY720, also called fingolimod, given to mice once a day for three days eliminated an infection by a virus that can cause meningitis, an inflammation of the membranes surrounding the brain and spinal cord. The findings suggest the drug, which boosted anti-viral immune responses in the mice, may be useful against viruses that cause high-level, long-lasting infections in people such as hepatitis C and HIV, the researchers said. Microbiologist and immunologist John Altman of Emory University in Atlanta, who led the study, said the researchers plan to assess the effects of the drug on other viruses including the monkey version of the AIDS virus. Altman, whose findings were published in the journal Nature, expressed cautious optimism that the drug might work against certain chronic viral infections in people. "We think it's crucial that we do experiments to check it out," Altman said in a telephone interview. The drug is generally considered to be an immunosuppressant that works to restrain the body's natural defenses. That could be helpful in multiple sclerosis, an autoimmune disease in which the immune system attacks body parts as if they were foreign invaders. But one effect of the drug seems to facilitate the immune response, the researchers said. FTY720 among other things traps white blood cells key soldiers in the immune system's fight against infections in the lymph nodes, Altman said. With viral infections, the lymph nodes are where the immune response can get primed and started, Altman said. Some viruses replicate themselves at high levels in lymph nodes, including the human immunodeficiency virus that causes AIDS. They tested the drug against a mouse virus called lymphocytic choriomeningitis, which causes chronic infections by escaping immune responses. "In the absence of treatment (with FTY720) we have an exhausted immune response. In the presence of treatment, we regain a robust cellular immune response," Altman said. Swiss drug maker Novartis said in June two multiple sclerosis patients taking FTY720 in clinical trials had problems with infections and one died, but the role of the drug in the cases was unclear. Novartis plans at the end of 2009 to seek approval by the European Union for FTY720 to treat MS, spokeswoman Valerie Tate said by e-mail. The drug is currently in late-stage trials. Altman said his study was backed by the U.S. government's National Institutes of Health and was not funded by Novartis.
[EX A]: MS drug may work against viral infection: study.

[EX Q]: Kudos! This story reported on the costs of the drug Lucentis as well as the less expensive Avastin. The story provided quantitative information about the possible impact on vision. But we wish there information about any measurement of the patients' perspective on whether they are functioning better after receiving this treatment versus standard treatment While the story did include the common side effect of the drug in the study, there were other potentially important complications that were not mentioned. The story mentioned that the results reported on were from a phase III clinical trial; it included information about the number of affected eyes included in the study, and the impact on vision. The story did not engage in overt disease mongering. Several experts in the field were quoted in this story. In presenting the outcome of the study, the story mentioned in passing treatments currently used for treating diabetic macular edema. The story also mentioned the existence of another drug, Avastin, which was reported as working the same way as the study medication. (A more accurate description comparing Avastin and Lucentis is that they contain the nearly identical active ingredient but the production methods are a little different.) It would have been nice to mention that there is an on-going trial comparing the effectiveness of these two medications for the treatment of macular degeneration (not the condition which was the disease in the study reported on.) The story was crystal clear that the drug reported on, Lucentis, is available as it is FDA approved for another condition; the story also mentioned that it is not yet FDA approved for treatment of diabetic macular edema. The story was very clear that this was a new use for a medication that is already on the market. The story provided some insight that the company underwriting the costs of this study had a very similar but less expensive drug which was FDA approved for other use. It would have been useful to include a little more information comparing the two medications. It might also have been nice to include some information about how the drug studied works as compared to laser treatment, the current standard. Does not appear to rely on a press release.
[EX A]: A Genentech Eye Treatment Is Found to Help Prevent Vision Loss in Diabetics

[EX Q]: Poland, Europe's largest poultry producer according to data from Eurostat, has not had an outbreak of bird flu since 2017. Andrzej Danielak, president of Polish Association of Breeders and Poultry Producers, said that three farms might be affected, with up to 350,000 birds at risk in a three kilometer radius. "Veterinary services are implementing virus eradication procedures in this situation," local authorities in Lubartowski county said in a press release issued on Tuesday, adding that the virus was a subtype of highly pathogenic H5N8 bird flu that can also threaten people The authorities said crisis meetings had been held, while footage from private broadcaster Polsat showed police cars blocking a road in the area.
[EX A]:
Poland hit by bird flu outbreak on turkey farms.